Clinical trial NCT04155580: A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Official title: A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Keywords: AML
Bone marrow
CMML
MDS
ASTX727
ASTX660
cIAP1
Cellular inhibitor of apoptosis protein
XIAP
CDAi
Cytidine deaminase inhibitor
Cedazuridine
Decitabine
Acute myeloid leukemia
Chronic myelomonocytic leukemia
Myelodysplastic syndrome
Lead sponsor: Astex Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2019-11-07
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.

Detailed description: This is a three-part dose escalation and dose expansion Phase 1 study of ASTX660 alone and in combination with ASTX727 in adults with R/R AML.

Part 1 is an open-label, single arm, dose escalation with ASTX660 in combination with ASTX727 at the standard fixed dose combination (FDC).

Part 2 is an open-label, randomized, dose escalation intended to evaluate ASTX660 as a monotherapy and ASTX660 in combination with ASTX727 FDC.

Part 3 is an exploratory single arm dose expansion to further expand the number of participants treated with ASTX660 in combination with ASTX727 FDC.

Eligibility criteria: Inclusion Criteria:

1. Have a projected life expectancy of at least 12 weeks, as assessed by the Investigator.
2. Have histological confirmation of AML by World Health Organization (WHO) 2016 criteria and are either:

   1. refractory to intensive induction chemotherapy OR
   2. relapsed after intensive induction chemotherapy or stem cell transplant OR
   3. relapsed after or refractory to treatment with molecularly targeted and/or low-intensity chemotherapeutic regimens.
3. Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.
4. Have adequate renal function as demonstrated by measured or calculated creatinine clearance ≥60 mL/min.
5. Have adequate liver function as demonstrated by:

   1. Aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN)
   2. Alanine aminotransferase (ALT) ≤2.5 × ULN
   3. Bilirubin ≤1.5 × ULN - unless considered due to leukemic organ involvement.
6. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group \[CTFG\]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.

Exclusion Criteria:

1. Poor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.
2. Known clinically active central nervous system (CNS) leukemia.
3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
4. Diagnosis of acute promyelocytic leukemia (M3 AML or APML).
5. Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
6. Graft Versus Host Disease (GVHD), or any GVHD requiring treatment with immunosuppression. Any GVHD treatment (including calcineurin inhibitors) must be discontinued at least 28 days prior to Day 1 of study treatment.
7. Presence of persistent toxicities of Grade \>1 from prior treatment including chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, and surgery (except for alopecia).
8. Hypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients.
9. Liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
10. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participant safety, or the integrity of study outcomes, or interfere with the absorption or metabolism of ASTX660 or ASTX727.
11. History of, or at risk for, cardiac disease.
12. Known human immunodeficiency virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV) infection (participants with laboratory evidence of no active replication will be permitted).
13. Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the participant to high risk of noncompliance with the protocol treatment or assessments.
14. Treated with any investigational therapy within 2 weeks of the first dose of study treatment or treatment with a myelosuppressive therapy within 4 weeks of the first dose of study treatment.
15. In Parts 1 and 2, prior treatment with decitabine for more than 2 cycles. In Part 3, any treatment with an HMA (azacitidine or decitabine, for more than one cycle).
16. Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to ASTX660-02 (Note: G-tube administration is not allowed).

Primary outcomes:
measure: Safety Assessment: Number of participants with treatment-emergent adverse events (TEAEs)
timeFrame: Up to 30 months
Secondary outcomes:
measure: Response rate: Number of participants achieving complete response (CR), complete response with incomplete hematological recovery (CRi), and partial response (PR) as determined by the European LeukemiaNet (ELN) 2017 response criteria for AML
timeFrame: Up to 30 months
measure: Time to response: Time from first dose to the first documented evidence of response
timeFrame: Up to 30 months
measure: Duration of response: Time from the start of response until disease progression or relapse
timeFrame: Up to 30 months
measure: Overall survival: Time since first dose until death due to any cause
timeFrame: Up to 30 months
measure: Composite complete response: Number of participants (sum of CR+CRi)
timeFrame: Up to 30 months
measure: Complete response with partial hematological recovery (CRh): Number of participants
timeFrame: Up to Month 30
measure: Pharmacokinetic parameter: Area under the curve (AUC)
timeFrame: On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
measure: Pharmacokinetic parameter: Maximum plasma concentration (Cmax)
timeFrame: On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
measure: Pharmacokinetic parameter: Minimum plasma concentration (Cmin)
timeFrame: On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
measure: Pharmacokinetic parameter: Time to reach maximum plasma concentration (Tmax)
timeFrame: On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
measure: Pharmacokinetic parameter: Half-life (t½)
timeFrame: On Days 1, 5 and 6 of Cycle 1 and Day 1 of Cycle 2 (28 days per cycle)
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: New Haven
country: United States
facility: Smilow Cancer Hospital
state: Connecticut
city: Miami
country: United States
facility: Sylvester Comprehensive Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Northside Hospital - The Blood and Marrow Transplant Group of Georgia
state: Georgia
city: Chicago
country: United States
facility: The University of Chicago Medical Center
state: Illinois
city: Indianapolis
country: United States
facility: Franciscan Health Indianapolis (Blood and Marrow Transplantation)
state: Indiana
city: Fairway
country: United States
facility: The University of Kansas Clinical Research Center
state: Kansas
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Buffalo
country: United States
facility: Roswell Park Comprehensive Cancer Center
state: New York
city: New York
country: United States
facility: New York University Langone Health
state: New York
city: New York
country: United States
facility: Mount Sinai Medical Center
state: New York
city: Chapel Hill
country: United States
facility: Lineberger Comprehensive Cancer Center
state: North Carolina
city: Columbus
country: United States
facility: Ohio State University Comprehensive Cancer Center
state: Ohio
city: Nashville
country: United States
facility: Vanderbilt - Ingram Cancer Center
state: Tennessee
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
References: